Success Metrics

Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
3
75%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Terminated(1)
Other(2)

Detailed Status

unknown2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (75.0%)
Phase 31 (25.0%)

Trials by Status

recruiting125%
unknown250%
terminated125%

Recent Activity

1 active trials
Showing 4 of 4
terminatedphase_2

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

NCT05161572
recruitingphase_3

Study of Comparing of With and Without Sequential Therapy of S-1

NCT05813015
unknownphase_2

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

NCT03904225
unknownphase_2

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

NCT04377048

Clinical Trials (4)

Showing 4 of 4 trials
NCT05161572Phase 2

Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer

Terminated
NCT05813015Phase 3

Study of Comparing of With and Without Sequential Therapy of S-1

Recruiting
NCT03904225Phase 2

Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis

Unknown
NCT04377048Phase 2

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4